554 related articles for article (PubMed ID: 31263129)
1. HNRNPA2/B1 is upregulated in endocrine-resistant LCC9 breast cancer cells and alters the miRNA transcriptome when overexpressed in MCF-7 cells.
Klinge CM; Piell KM; Tooley CS; Rouchka EC
Sci Rep; 2019 Jul; 9(1):9430. PubMed ID: 31263129
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA regulation of the serine synthesis pathway in endocrine-resistant breast cancer cells.
Petri BJ; Piell KM; Wilt AE; Howser AD; Winkler L; Whitworth MR; Valdes BL; Lehman NL; Clem BF; Klinge CM
Endocr Relat Cancer; 2023 Nov; 30(11):. PubMed ID: 37650685
[TBL] [Abstract][Full Text] [Related]
3. HNRNPA2B1 regulates tamoxifen- and fulvestrant-sensitivity and hallmarks of endocrine resistance in breast cancer cells.
Petri BJ; Piell KM; South Whitt GC; Wilt AE; Poulton CC; Lehman NL; Clem BF; Nystoriak MA; Wysoczynski M; Klinge CM
Cancer Lett; 2021 Oct; 518():152-168. PubMed ID: 34273466
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneous nuclear ribonucleoprotein A2/B1 is a negative regulator of human breast cancer metastasis by maintaining the balance of multiple genes and pathways.
Liu Y; Li H; Liu F; Gao LB; Han R; Chen C; Ding X; Li S; Lu K; Yang L; Tian HM; Chen BB; Li X; Xu DH; Deng XL; Shi SL
EBioMedicine; 2020 Jan; 51():102583. PubMed ID: 31901866
[TBL] [Abstract][Full Text] [Related]
5. The miR-29 transcriptome in endocrine-sensitive and resistant breast cancer cells.
Muluhngwi P; Alizadeh-Rad N; Vittitow SL; Kalbfleisch TS; Klinge CM
Sci Rep; 2017 Jul; 7(1):5205. PubMed ID: 28701793
[TBL] [Abstract][Full Text] [Related]
6. HnRNPA2B1 promotes the proliferation of breast cancer MCF-7 cells via the STAT3 pathway.
Gao LB; Zhu XL; Shi JX; Yang L; Xu ZQ; Shi SL
J Cell Biochem; 2021 Apr; 122(3-4):472-484. PubMed ID: 33399232
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells.
Muluhngwi P; Krishna A; Vittitow SL; Napier JT; Richardson KM; Ellis M; Mott JL; Klinge CM
Cancer Lett; 2017 Mar; 388():230-238. PubMed ID: 27986463
[TBL] [Abstract][Full Text] [Related]
8. hnRNPA2/B1 activates cyclooxygenase-2 and promotes tumor growth in human lung cancers.
Xuan Y; Wang J; Ban L; Lu JJ; Yi C; Li Z; Yu W; Li M; Xu T; Yang W; Tang Z; Tang R; Xiao X; Meng S; Chen Y; Liu Q; Huang W; Guo W; Cui X; Deng W
Mol Oncol; 2016 Apr; 10(4):610-24. PubMed ID: 26774881
[TBL] [Abstract][Full Text] [Related]
9. MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells.
Zhong S; Li W; Chen Z; Xu J; Zhao J
Gene; 2013 Nov; 531(1):8-14. PubMed ID: 23994196
[TBL] [Abstract][Full Text] [Related]
10. miRNA expression patterns in chemoresistant breast cancer tissues.
Lv J; Xia K; Xu P; Sun E; Ma J; Gao S; Zhou Q; Zhang M; Wang F; Chen F; Zhou P; Fu Z; Xie H
Biomed Pharmacother; 2014 Oct; 68(8):935-42. PubMed ID: 25451164
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of microRNA-27b-3p enhances tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1 expression.
Zhu J; Zou Z; Nie P; Kou X; Wu B; Wang S; Song Z; He J
Cell Death Dis; 2016 Nov; 7(11):e2454. PubMed ID: 27809310
[TBL] [Abstract][Full Text] [Related]
12.
Ma Y; Yang L; Li R
Genet Test Mol Biomarkers; 2020 Nov; 24(11):701-707. PubMed ID: 32985904
[No Abstract] [Full Text] [Related]
13. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1.
Miller TE; Ghoshal K; Ramaswamy B; Roy S; Datta J; Shapiro CL; Jacob S; Majumder S
J Biol Chem; 2008 Oct; 283(44):29897-903. PubMed ID: 18708351
[TBL] [Abstract][Full Text] [Related]
14. [Urothelial carcinoma-associated 1 enhances tamoxifen resistance in breast cancer cells through competitively inhibiting miR-18a].
Li XN; Liu AH; Tang X; Ren Y
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Apr; 49(2):295-302. PubMed ID: 28416841
[TBL] [Abstract][Full Text] [Related]
15. miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22.
Li J; Lu M; Jin J; Lu X; Xu T; Jin S
Cell Physiol Biochem; 2018; 50(1):136-149. PubMed ID: 30278449
[TBL] [Abstract][Full Text] [Related]
16. Liposomal curcumin alters chemosensitivity of breast cancer cells to Adriamycin via regulating microRNA expression.
Zhou S; Li J; Xu H; Zhang S; Chen X; Chen W; Yang S; Zhong S; Zhao J; Tang J
Gene; 2017 Jul; 622():1-12. PubMed ID: 28431975
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-574-3p, identified by microRNA library-based functional screening, modulates tamoxifen response in breast cancer.
Ujihira T; Ikeda K; Suzuki T; Yamaga R; Sato W; Horie-Inoue K; Shigekawa T; Osaki A; Saeki T; Okamoto K; Takeda S; Inoue S
Sci Rep; 2015 Jan; 5():7641. PubMed ID: 25560734
[TBL] [Abstract][Full Text] [Related]
18. Differential microRNA profiles between fulvestrant-resistant and tamoxifen-resistant human breast cancer cells.
Zhou Q; Zeng H; Ye P; Shi Y; Guo J; Long X
Anticancer Drugs; 2018 Jul; 29(6):539-548. PubMed ID: 29557813
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors.
Cittelly DM; Das PM; Spoelstra NS; Edgerton SM; Richer JK; Thor AD; Jones FE
Mol Cancer; 2010 Dec; 9():317. PubMed ID: 21172025
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
